Beyond Creatinine: First Real-World Evidence Highlights Proenkephalin A 119–159 (penKid) as a Valuable Kidney Function Biomarker

April 16, 2025 4:30 AM

Diagnostic company SphingoTec GmbH ("SphingoTec") announces the publication of real-world data on the effectiveness of Proenkephalin A 119-159 (penKid) in improving kidney function assessment in intensive care units (ICUs) (1). This study confirms penKid's value in identifying high-risk patients at admission and supporting the management of renal replacement therapy (1). The published data complement a recent review from the Mayo Clinic that...

Read more

ICN Launches New Report and Survey Warning of Deepening Global Nursing Crisis but Offering Solutions

April 16, 2025 1:00 AM

The International Council of Nurses (ICN) today launched a landmark report backed up by a new survey, warning of a deepening crisis in the wellbeing of the global nursing workforce and providing compelling evidence for urgent investment in nurses to improve health outcomes, strengthen economies, and build more resilient societies. ICN says the report and survey launched ahead of International Nurses Day (IND) 12 May, provide concrete evidence of...

Read more

Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1

April 16, 2025 12:00 AM

Ascelia Pharma (STO:ACE) - The exercise period for warrants series TO 1 ("TO 1") in Ascelia Pharma AB ("Ascelia Pharma" or the "Company") ended on 15 April 2025. The outcome shows that a total of 19,919,494 TO 1 were exercised for subscription of 19,919,494 new ordinary shares, corresponding to a subscription rate of approximately 96 percent. Ascelia Pharma thus receives proceeds of approximately SEK 43 million before issue costs.The exercise...

Read more

Supplement Manufacturing Partner, Inc. Issues Recall on Dorado Nutrition Brand Spermidine Supplement 10mg Vegetable Capsules (Spermidine 3HCL) Due To Undeclared Wheat Allergen

April 16, 2025 12:00 AM

Supplement Manufacturing Partners, Inc. is recalling Dorado Nutrition brand Spermidine Maximum Strength 10 MG per serving, because it contains undeclared wheat. People who have an allergy or severe sensitivity to wheat run the risk of serious or life-threatening allergic reaction if they consume this product.Spermidine Maximum Strength 10 MG per serving was sold online at Amazon from 05/22/2024 to 04/04/2025.Product was also sold in Germany as...

Read more

NHI Announces First Quarter 2025 Earnings Release and Conference Call Dates

April 15, 2025 5:15 PM

National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the first quarter ended March 31, 2025. NHI plans to issue its earnings release after the market closes on Monday, May 5, 2025, and will host a conference call on the following day, Tuesday, May 6, 2025, at 11:00 a.m. Eastern Time to discuss the results. The number to call for this interactive teleconference is (888) 506-0062, with the access code...

Read more

MedShift Unveils Velocity Advanced Reporting: Empowering Businesses with AI-Driven Insights and Data Visualization

April 15, 2025 5:10 PM

MedShift, a leading enterprise SaaS company, proudly announces the launch of Velocity Advanced Reporting, a suite of upgraded features for Velocity's core reporting module. Designed to empower North American businesses with advanced data analysis and visualization capabilities, this module leverages artificial intelligence (AI) to deliver actionable insights, further solidifying MedShift's position as an innovator in enterprise SaaS...

Read more

Vogenx, Inc. to Present Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2025 Annual Conference

April 15, 2025 2:45 PM

Vogenx, Inc., a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that it will present phase 2 clinical data from Study VGX-001-012 (NCT05721729) at the Endocrine Society (ENDO) 2025 Annual Conference highlighting Mizagliflozin's effect on hypoglycemic events and relevant pharmacodynamic indicators in patients diagnosed with post bariatric hypoglycemia (PBH)....

Read more

Conference Call on Interim Report January-March 2025

April 15, 2025 2:30 PM

GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025. The presentation will be held in English.Time: Thursday, April 24 at 2.00 pm CET / 8.00 am ESTIf you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions....

Read more

Brazil's Digital Healthcare Boom Faces Critical Hurdles, Reveals Black Book Research

April 15, 2025 1:00 PM

Despite substantial advancements and increasing investments, Brazil's Electronic Health Record (EHR) sector faces critical obstacles, according to independent research conducted by Black Book Research. Interviews with 203 Brazilian hospital and physician organizations and 24 government healthcare IT policy officials revealed a complex mix of optimism and concern regarding digital healthcare initiatives.Market Growth Fueled by Urban...

Read more

Belhaven Biopharma Announces Positive Data From Their Nasdepi(R) Dose Confirmation Study in Patients With and Without Allergic Rhinitis

April 15, 2025 10:30 AM

Belhaven Biopharma, a leader in innovative treatments for severe allergic reactions, is pleased to share promising results from its dose confirmational clinical trial of Nasdepi®. The study substantiates a dose that is comparable to approved intramuscular injections by evaluating the pharmacokinetic and pharmacodynamic effects in subjects with and without induced allergic rhinitis.Key Takeaways:This study validates the commercial dose for FDA...

Read more

Arthritis Foundation Launches Green Heart Fridays: A Nationwide Free Art Activation for Arthritis Awareness Month

April 15, 2025 10:00 AM

May is Arthritis Awareness Month, and the Arthritis Foundation, the number one resource for arthritis resources and information, is introducing Green Heart Fridays. This nationwide free art activation is aimed at uniting and inspiring the arthritis community while raising awareness of arthritis, the nation's #1 cause of disability. Central to the campaign is the Green Heart - a powerful symbol of support, resilience and connection for the...

Read more

Ascend Aesthetic Partners Announces 2025-2026 Fellowship Matches at Hedden, Gunn & Halka in Alabama and Ponte Vedra Plastic Surgery in Florida

April 15, 2025 10:00 AM

Ascend Aesthetic Partners, a national network of leading aesthetic surgeons, has announced its 2025-2026 fellowship matches-an initiative designed to advance the next generation of aesthetic specialists through immersive, practice-based training.The 2026 Ascend fellows have been matched with two of the network's leading practices. Hedden, Gunn & Halka Plastic Surgery of Birmingham, Alabama, welcomes Timothy Stoddard, M.D., from the Medical...

Read more

CS Diagnostics Corp. is Entering into a $5 Million Loan Agreement with SAN ART CAPITAL SAS

April 15, 2025 9:35 AM

Neuss, Germany: CS Diagnostics Corp. is pleased to announce that it has received a Letter of Intent from SAN ART CAPITAL SAS, a leading advisory and investment management firm based in Bogotá, Colombia for a proposed USD 5,000,000 (five million US dollars) equity loan to support the production and commercialization of CS Diagnostic Corp.'s assets and strategic developments.The proposed financing outlined in a Letter of Intent issued by Carlos...

Read more

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

April 15, 2025 9:30 AM

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget study has been accepted for presentation as an oral rapid e-poster at MASCC's June 26-28, 2025 Annual Meeting in Seattle, Washington. The authors include Pravin Chaturvedi, PhD, who is...

Read more

MDelite Donates TrilogyPro Laser to BJC Children’s Hospital to Expand Teen Pilonidal Disease Treatment

April 15, 2025 9:00 AM

MDelite, a leading provider of aesthetic and vision technology, has donated its TrilogyPro laser hair removal system to BJC Children's Hospital to support pediatric patients suffering from pilonidal disease-a chronic, painful condition that commonly affects teens and young adults. The donation supports BJC's Pediatric Acute Wound Service (PAWS), where pilonidal disease is among the most frequently treated conditions. The disease develops near...

Read more

Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program

April 15, 2025 8:50 AM

As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with various healthcare systems and has a keen interest in researching patient-centered care models and innovative digital healthcare tools."I really think that technology can help us move the healthcare system to be more proactive," says Maria.With support from the Gilead Research Scholars Program (RSP), Maria is utilizing a remote...

Read more

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

April 15, 2025 8:30 AM

Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints as early as week 4, which occurred after just four...

Read more

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

April 15, 2025 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced completion of Part 1 of its second clinical trial to evaluate PF614-MPAR for overdose protection. PF614-MPAR-102 demonstrated that the combined Ensysce TAAPTM and MPAR® technologies can deliver strong relief...

Read more

CEO of Wellgistics Health Converts $1.5 Million of Debt to Equity at IPO Price

April 15, 2025 7:40 AM

Wellgistics Health, Inc. (NASDAQ:WGRX) (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that it has entered into an amendment to the Membership Interest Purchase Agreement with Wellgistics LLC and Wellgistics LLC's former owners to convert a significant cash payment owed by the Company into shares of the Company's common...

Read more

Curiteva Surpasses 5,000 Levels Treated with Its Novel Inspire Cervical 3D Printed Trabecular PEEK

April 15, 2025 7:00 AM

Curiteva, Inc., a pioneering technology and manufacturing company, is pleased to announce a significant achievement with over 5,000 levels successfully treated using the Inspire Cervical implant, just two years after its first surgical use in April 2023. This milestone highlights the continued adoption of the novel 3D printed trabecular PEEK implant, further establishing Curiteva's presence as a leader in spine innovation.Spine surgeons continue...

Read more